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Abstract
Background: Current real-life information from all-comers registries from middle and east Europe 
about the incidence and type of complications during long-term follow-up of patients with cardioverters-
defibrillators (ICD) and cardiac resynchronization devices-defibrillators (CRT-D) is still insufficient. 
The aim of the study was to assess the incidence and determinants of short- and long-term complications 
related to implantable ICD and CRT-D.
Methods: We studied 1,105 recipients hospitalized in our center in 2009–2013, followed for a mean of 
2.4 years (total of 2,652 patient-years). The independent association between ICD and CRT-D recipi-
ents’ and implantation-procedures’ characteristics with the incidence of complications was analyzed 
using multivariable Cox regression analysis.
Results: In 2-month post-procedural period, 124 (11.2%) patients developed complications. Independ-
ent predictors of short-term complications (within 2 months) were: atrial fibrillation, dual chamber ICD 
implantation, and use of antiplatelet therapy or coumarin. Twenty-seven (2.44%) patients experienced 
complications, mostly lead-related (n = 21). Independent predictors of long-term complications (2–12 
months after implantation) were atrial fibrillation and dual chamber ICD implantation.
Conclusions: Despite significant technological progress and operators’ experience, the occurrence of 
complications in ICD and CRT-D recipients is still substantial. Majority of complications are recorded 
in the early post-implantation phase. Analysis of independent predictors of complications seem to be 
essential in helping to reduce adverse events in the future and strongly supports the need for routine 
follow-up. (Cardiol J 2017; 24, 5: 515–522)
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Introduction
Indications for implantation of cardioverters-
defibrillators (ICD) and cardiac resynchronization 
devices-defibrillators (CRT-D) widen after results 
of new trials and with updated guidelines [1, 2]. In 
Poland, the amount of patients with ICD implan-
tations in 2007–2010 increased threefold — from 
2,500 to 8,000/year [3]. These numbers are likely 
to increase in time as a result of quickly expanding 
group of patients with indications for implantation 
of ICD or CRT-D [4]. Results of randomized trials 
proved that cardiac implantable electronic devices 
(CIEDs) — ICD and CRT-D implanted in primary 
516 www.cardiologyjournal.org
Cardiology Journal 2017, Vol. 24, No. 5
and secondary prevention of sudden cardiac death 
are efficacious and prolong life [5, 6]. However, data 
assessing real-life, beyond clinical trials, function-
ing of patients with ICD or CRT-D, especially along 
with the technological development of the devices 
should be updated and geographical region of Eu-
rope should be taken into consideration and results 
compared with the ones available from registries 
from well-developed countries [7]. In everyday clin-
ical practice, indications are sometimes off-label and 
population of patients is more heterogeneous [8]. 
Therefore, we created an all-comers Silesian 
Center Defibrillator registry of over 1,000 of subse-
quent patients with implantation of ICD/CRT-D and 
used data from hospitalizations, remote monitoring 
(RM) database and Polish National Health Fund 
(NHF) records to assess clinical characteristics, 
in-hospital complications, and 1-year mortality 
of the analyzed population. The registry can be 
important source of information complementary 
to data obtained from clinical trials.
Methods
Study population and data sources
Data of 1,105 patients hospitalized in aca-
demic, high-volume CIEDs implantation center (an 
average of 1,000 implantations/year), in 2009–2013 
with left ventricular (LV) ejection fraction (EF) 
≤ 35% and who met current practice guidelines 
indications for implantation of ICD or CRT-D, and 
were included in Silesian Center Defibrillator reg-
istry were used. A group of 512 (46.3%) patients 
had active RM system and data transmitted were 
analyzed by qualified team consisting of electro-
physiology nurse and in-training doctors under 
supervision of experienced cardiologists. Medi-
cal history, clinical data of the patients, collected 
during initial hospitalization were retrieved from 
prospectively recorded Electronic Database in our 
center by the attending physician. Furthermore, 
implantation procedure characteristics such as 
type of implanted ICD, which were also recorded 
to quantify its potential, added predictive value 
for subsequent complications. We obtained data 
regarding complications and mortality by link-
ing registry records with NHF records, the only 
payer for medical procedures in Poland. All the 
hospitalizations after implantation procedures were 
analyzed with regard of the presence of complica-
tions related to index implantation procedure. Data 
concerning control visits in specialist outpatient 
clinics and primary health care were analyzed in 
a similar way. The data concerning the reported 
disease entities and procedures according to the 
ICD-10 and ICD-9 classifications were anonymized. 
Collecting the information concerning an individual 
patient was possible by tracking the hospital reg-
istration number and encoded PESEL (Personal 
Identification) number. The follow-up data with the 
accompanying exact dates of death were obtained 
from the official NHF records.
Due to retrospective character of the study, 
no approval from local bioethical committee was 
obtained.
Data analysis
The following variables were analyzed: gender, 
age, type of implanted CIED (single/dual chamber 
ICD, CRT-D), etiology of heart failure, functional 
class according to New York Heart Association 
(NYHA) score, co-morbidities, previous revascu-
larization in case of coronary artery disease, 1-year 
mortality related to type of device implanted, 
echocardiography parameters, electrocardiographic 
parameters, atrial status and pharmacotherapy. All 
the patients underwent local antibiotic prophylaxis 
regimen pre-procedural single dose of cefazolin 1 g 
intravenously or prolonged 5-day antibiotic therapy 
in case of an implantation procedure lasting over 
1 h or in patients with impaired immunity (diabetic, 
chronic kidney failure, neoplastic disease, over 
75 years old). The primary end-point was analysis 
of the complications. The complications were de-
fined according to well known and widely observed 
in daily practice: traumatic complications, lead-
related complications, pocket and clinical compli-
cations, and problems with connection screw. We 
divided these complications into those occurring 
during the device therapy optimization and lead 
maturation phase (within 2 months after initial pro-
cedure of ICD/CRT-D implantation and likely re-
lated to the implantation procedure: short-term-2-
month complications), and complications emerging 
during follow-up (long-term complications) [9, 10]. 
The incidence rate of complications is reported as 
the number of events and also as an incidence rate 
per 1,000 person-years. As patients could have > 1 
complication recorded, multiple complications 
were not considered separately.
Statistical analysis
The incidence of short- and long-term ICD/
CRT-D complications was assessed. Survival 
free time from any ICD/CRT-D complication was 
estimated using the Kaplan-Meier method [11]. 
The prognostic relevance of the various baseline 
variables on the occurrence of both short- and 
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long-term complications was assessed with Cox 
proportional hazards regression models with re-
sults expressed as hazard ratios (HR) and 95% 
confidence intervals (CI). We initially decided 
to include all clinical, demographic and type of 
implanted device data from medical history as 
potential predictors and all-cause mortality. All-
cause mortality was determined to be considered 
a complication and it was taken into account in the 
Kaplan-Meier method and Cox proportional hazard 
regression model mentioned above. Our data come 
from a registry of high-energy implantable cardiac 
devices and, according to current European Society 
of Cardiology guidelines, only the patients with of 
at least 1-year life expectancy were qualified for 
ICD/CRT-D implantation. This is why it seems rea-
sonable for all-cause mortality to be included in the 
analysis of complications as it was not an expected 
incident in this group of patients. Moreover, due 
to limitations of the registry, it is not possible to 
assess the cause of death, nor select deaths related 
to the procedure of ICD/CRT implantation.
For both outcomes, all predictors were simul-
taneously included in the model. We used a p value 
of ≤ 0.3 in univariate analysis to include a variable 
in the multivariable analysis model [12]. A 2-sided 
p-value ≤ 0.05 was considered significant. The 
STATISTICA 10 software (StarSoft Inc., Tulusa, 
Oklahoma), MedCalc (MedCalc Software, Maria-
kerke, Belgium) and SPSS ver. 17.0.1 (SPSS, Inc., 
Chicago, Illinois) were used for all calculations.
Results
We analyzed population of 1,105 patients, fol-
lowed for a mean of 2.4 years, resulting in a total 
of 2,652 patient-years. Mean age 60.3 ± 9.6 years 
and 900 (81.5%) patients were male. Mean LVEF 
was 25% and 956 (86.5%) patients fulfilled current 
indications for implantation of ICD or CRT-D in 
primary prevention. Most (40.9%) patients under-
went implantation of a dual-chamber ICD. Some 
patients in the dual-chamber ICD group had dual-
chamber pacemakers implanted previously and 
yet with lowered EF of 35% or below; others had 
dual-chamber ICD implanted according to current 
guidelines or out-of-label criteria. CRT-D criteria 
were met in 400 (36.2%) cases and single-chamber 
ICD in 253 (22.9%). At the time of qualification, 364 
(33.9%) patients were in NYHA class II, 608 (55%) 
in NYHA class III, and 133 (11.1%) in ambulatory 
NYHA class IV. In most (63%) cases, the etiology of 
heart failure was ischemic. A group of 512 (46.3%) 
patients, beside regular visits in cardiology day 
clinic, activated remote monitoring system and 
were supervised by telemetric means. Twelve- 
-month mortality in the entire group amounted to 
7.5%. More details including basic clinical charac-
teristics are shown in Table 1.
ICD/CRT-D-related complications
Figure 1 illustrates survival free from any ICD/ 
/CRT-D complication. The curve shows a steep 
slope in the first 5 months followed by a more stable 
decline, indicating a high incidence of ICD/CRT-D 
complications early after implantation.
Traumatic complications
According to their character, traumatic compli-
cations occurr mainly during the index procedure. 
The most frequently observed traumatic complica-
tion was pneumothorax in 13 (1.2%) patients and 
5 of them had to be drained. All of the electrodes 
in this group of patients were implanted via subcla-
vian vein puncture. Two of pneumothorax patients 
were earlier diagnosed with chronic pulmonary 
obstructive disease (COPD). Four (30.8%) pa-
tients in pneumothorax group were implanted with 
1 electrode, 7 (53.8%) patients with 2 electrodes 
and 2 (15.4%) patients with 3 electrodes. Cardiac 
structure perforation during first 2 months of 
follow-up was rather a rare complication (0.1%). 
Pericardial infusion was seen in 4 (0.4%) patients 
and 1 person developed hemothorax treated with 
drainage. Only 1 patient, in whom ventricle defi-
brillation lead was implanted in the apex of right 
ventricle, experienced perforation treated by an 
uncomplicated pericardiocentesis.
Lead-related complications
The most frequent early lead-related compli-
cation was lead dislocation. However, that type 
of complication was also commonly recorded in 
late-term follow-up. Reposition due to electrode 
dislocation in 2 months was needed in 18 patients 
(5 atrial electrodes, 6 right ventricle and 7 elec-
trodes placed over LV).
Pocket complications
The most common type of complication oc-
curring in early period of the observation was 
pocket-related complication. Sixty-eight (6.1%) 
patients developed a pocket hematoma. Twenty-
four (32.4%) patients with hemorrhagic complica-
tions were treated with acetylsalicylic acid (ASA), 
21 (28.4%) with dual antiplatelet therapy (DAPT), 
42 (56.8%) patients were on oral anticoagulants 
(OAC), 25 (33.8%) patients were treated with 
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unfractionated heparin (UFH); 22 (29.7%) patients 
were on bridge therapy (either UFH or low-mole-
cule weight heparin [LMWH]) and 19 (25.7%) pa-
tients were treated with both antiplatelet drugs and 
OAC. However, in only 6 (0.54%) patients blood 
transfusion was required. Only 1 (0.1%) patient 
in short-term follow-up, and 4 (0.4%) patients in 
long-term follow-up developed a pocket infection. 
Those numbers are much lower when compared 
to other trials or registries. The exact reason of 
such a low infection rate might be due to previous 
local policy of prolonged (up to 3–5 days) antibi-
otic therapy with cefazolin in case or prolonged 
implantation procedure (over 1 h) or in patients 
with impaired immunity (diabetic, chronic kidney 
failure, neoplastic disease, over 75 years old).
Clinical complications such as cardiac arrest 
or pulmonary edema were all recorded during 
index hospitalization. All cardiac arrest cases 
were due to ventricular tachycardia/ventricular 
fibrillation and happened during the implantation 
procedure most likely due to mechanical irritation 
of endocardium by defibrillation lead and all were 
followed by a successful external defibrillation 
and resuscitation. The all-cause mortality data 
with the accompanying exact dates of deaths were 
obtained from official mortality records from the 
NHF. Unfortunately, it is impossible for us to state 
with certainty what were the reasons of deaths 
shown in Table 2 (cardiovascular or other), but all 
of them occurred after discharge from the hospital. 
Figure 1. Survival free from implantable cardioverter-
defibrillator/cardiac resynchronization therapy-defibril-
lator complications.
Table 1. Baseline patient characteristics and 
12-month all-cause mortality.
Variable Analyzed group  
(n = 1105)
Age [years] 60.3 ± 9.6
Male 900 (81.5%)
LV ejection fraction [%] 25 ± 5.5
LV end-diastolic diameter [mm] 65.7 ± 9.15
LV end-systolic diameter [mm] 53.7 ± 10.5
LV end-diastolic volume [mL] 140 ± 77.9
LV end-systolic volume [mL] 190 ± 72.3
NYHA:
Class II 364 (33.9%)
Class III 608 (55%)
Class IV 133 (11.1%)
Intrinsic QRS duration [ms] 122.5 ± 32.1
Telemonitoring 512 (46.3%)
Implanted device:
Single chamber ICD 253 (22.9%)
Dual chamber ICD 452 (40.9%)
CRT-D 400 (36.2%)
Up-grade ICD to CRT-D 47 (4.3%)




Ischemic cardiomyopathy 696 (63%)
Prior myocardial infarction 508 (46%)
Prior PCI 497 (45%)
Prior coronary bypass 176 (16%)
Stroke 55 (5%)
Hypertension 574 (52%)
Atrial fibrillation/flutter 353 (30.2%)
Diabetes 431 (39%)
Hyperlipidemia 464 (41%)
Renal insufficiency (class ≤ 3) 309 (28%)
Mean NT-proBNP [pg/mL] 2739.4 ± 234.4







Aldosterone receptor blocker 939 (86%)








12-month all-cause mortality 83 (7.5%)
ACEI/ARB — angiotensin converting enzyme inhibitor/angiotensin 
receptor blocker; CRP — C-reactive protein; CRT-D — cardiac 
resynchronization the rapy-defibrillator; ICD — implantable cardio-
verter-defibrillator; LBBB — left bundle branch block; LV — left 
ventricular; NT-proBNP — N-terminal pro-B-type natriuretic peptide; 
NYHA — New York Heart Association; PCI — percutaneous coro-
nary intervention; RBBB — right bundle branch block
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Table 2. Complication during first 2 months after implantation procedure and during long-term follow-up.
Within 2 months During follow-up Rate (95% CI)#
All traumatic complications 23 (2.1%) 1 (0.1%) 9.26 (5.94–13.79)
Perforation of cardiac structure 1 (0.1%) 1 (0.1%) 0.77 (0.09–2.79)
Pneumothorax 13 (1.2%) 0 (0%) 5.02 (2.67–8.58)
Hemothorax 1 (0.1%) 0 (0%) 0.39 (0.01–2.15)
Pericardial effusion 4 (0.4%) 0 (0%) 1.54 (0.42–3.95)
Coronary sinus dissection 4 (0.4%) 0 (0%) 1.54 (0.42–3.95)
All lead-related complications 26 (2.35%) 21 (1.9%) 18.14 (13.3–24.3)
Lead damage 5 (0.45%) 10 (0.9%) 5.79 (3.24–9.55)
RA lead dislocation 5 (0.45%) 1 (0.1%) 2.32 (0.85–5.04)
RV lead dislocation 6 (0.54%) 1 (0.1%) 2.72 (1.09–5.57)
LV lead dislocation 7 (0.6%) 5 (0.45%) 4.63 (2.39–8.09)
Insulation problem 0 (0%) 0 (0%) 0.00
Infection 0 (0%) 4 (0.4%) 1.54 (0.42–3.95)
High defibrillation threshold requiring  
subcutaneous lead implantation
3 (0.3%) 0 (0%) 1.16 (0.24–3.38)
All pocket complications 72 (6.5%) 5 (0.45%) 29.72 (23.4–37.1)
Hematoma 68 (6.1%) 1 (0.1%) 26.64 (20.7–33.7)
Hematoma requiring blood transfusion 6 (0.54%) 0 (0%) 2.32 (0.85–5.04)
Difficult to control bleeding 3 (0.3%) 0 (0%) 1.16 (0.24–3.38)
Infection 1 (0.1%) 4 (0.4%) 1.93 (0.63–4.5)
Skin erosion 0 (0%) 0 (0%) 0.00
Clinical complications
Cardiac arrest 4 (0.4%) NA 1.54 (0.42–3.95)
Pulmonary edema 13 (1.2%) NA 5.02 (2.67–8.58)
Death* 17 (1.53%) 180 (16.3%) 76.02 (65.8–87.4)
Others
Problem with connection screw 3 (0.3%) 0 (0%) 1.16 (0.24–3.38)
Number of patients experiencing complications† 124 (11.2%) 27 (2.44%) 46.7 (41.2–53.8)
#Rate indicates the number of patients experiencing complication per 1,000 patient years at risk after implantation; *All-cause mortality;  
†Excluding clinical complications; CI — confidence interval; LV — left ventricle; NA — not available; RA — right atrial; RV — right ventricle
Table 3. Predictors of 2-month and long-term complications in multivariable analysis.
Predictors Multivariable analysis: HR (95% CI); p
Within 2 months During follow-up
Atrial fibrillation 2.15 (1.40–3.33); < 0.001 2.5 (1.58–3.94); < 0.001
Use of antiplatelet agent or coumarin 2.04 (10.1–4.13); 0.04 –
Dual-chamber cardioverter-defibrillator 2.01 (1.08–3.56); 0.045 2.08 (1.13–3.85); 0.019
Age at implantation* 1.01 (0.99–1.03); 0.09 1.03 (0.96–1.04); 0.15
CRT implantation 1.16 (0.62–2.16); 0.62 1.19 (0.64–2.19); 0.55
Use of heparin† 1.08 (0.63–1.82); 0.8 –
Body mass index# 0.49 (0.31–0.79); 0.002 0.52 (0.32–0.88); 0.002
Arterial hypertension 0.78 (0.50–1.20); 0.26 0.80 (0.53–1.22); 0.29
Ischemic cardiomyopathy 0.70 (0.42–1.18); 0.19 0.73 (0.32–1.28); 0.23
*Per 1-year increase; †Used < 24 h before and/or < 24 h after procedure; #Per 1-unit decrease; CI — confidence interval; CRT — cardiac  
resynchronization therapy; HR — hazard ratio
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More details including clinical complications are 
presented in Table 2. Patient- and implantation-
related predictors for short- and long-term ICD/ 
/CRT-D complications in multivariable analyses 
are shown in Table 3. Independent predictors for 
short-term ones (occurring within 2 months) were 
atrial fibrillation (AF; paroxysmal or fixed), dual 
chamber ICD implantation, and use of antiplatelet 
therapy or OAC. Independent predictors for long-
term ICD/CRT-D complications (occurring after 
2 months after implantation) were AF and dual 
chamber ICD implantation.
Discussion
The principal clinical implications from this 
investigation are the following. First — the study 
shows that despite current user-friendly and much 
smaller ICD/CRT-D devices and wide (including 
RM) possibilities for follow-up, the complication 
rate and associated morbidity remain significant 
and should be noted. Second — independent 
predictors for short-term complications (occur-
ring within 2 months) were AF (paroxysmal of 
fixed), dual chamber ICD implantation, and use of 
antiplatelet therapy or OAC, whereas independent 
predictors for long-term ICD/CRT-D complications 
were AF (paroxysmal of fixed) and dual chamber 
ICD implantation. Third — data obtained in the 
study of Polish population may be of assistance 
when compared by other institutions with their 
local outcome and complication rate. Identifica-
tion of high-risk patients would be useful for de-
creasing complication rate and help to adjust local 
procedures especially concerning venous access 
or bridge therapy. Moreover, the ability to predict 
patients at risk could lead to a more tailored alloca-
tion of resources with varying intensity of follow-up 
visits to the risk of the patient, thereby decreasing 
the heavy workload associated with device follow-
up, which leads to more cost-effectiveness.
Data regarding in-hospital complications fol-
lowing “high voltage” device implantation should 
be frequently updated to help controlling complica-
tions rate and improve outcomes by implement-
ing safer techniques and policies. Most available 
numbers are based on randomized controlled trials 
(RCT) results performed on selected groups of 
patients and therefore fewer complications may 
be observed than in an all-comers evaluation due 
to strict patient selection criteria and more expe-
rienced operators involved. In recent years, large, 
registry-based studies have emerged with more 
extensive estimates of complications, however, 
data available from many registries are restricted 
to in-hospital follow-up, leaving a large proportion 
of longer-term CIED complications unaccounted 
for [10]. Therefore, in this large Silesian Center 
Defibrillator registry, we analyzed baseline char-
acteristic of patients included in the registry and 
the incidence and predictors of early and long-term 
ICD/CRT-D follow-up complications. We consid-
ered complications within first 2 months early 
ones as this is a generally accepted time period in 
which complications directly related to an initial 
surgical procedure as device implantation will have 
emerged [13]. The frequent practice of publishing 
only in-hospital complications may significantly 
underestimate true complication occurrence.
Differences in definitions of complications 
resulting in a wide variance of outcomes as well 
as use of wide windows of time follow-up cause 
trouble with a valid comparison of published com-
plication rates. However, clinical characteristics of 
patients in our registry, even though coming from 
still developing European country with smaller 
resources and experience, is similar to the ones 
analyzed in American or Western European clinical 
trials and registries, with main differences in type 
of implanted devices — most patients hospital-
ized included in this trial had a dual-chamber ICD 
(40.9%) implanted, while in available results of 
studies and registries most common devices were 
single-chamber ICD [9, 10]. In our opinion, the fact 
that more dual-chamber ICDs were implanted in 
the analyzed populations may be a due to the fact 
that the choice of the type of CIED was left at that 
time to the discretion of the operator or referring 
physician and more frequently off-label. Those 
numbers have been changing in favor of single-
chamber ICD and CRT-D lately. Those results 
are in most aspects in-keeping with results from 
both prospective trials and registries, despite the 
fact the majority of implanted devices were dual-
chamber ICD and CRT-D and amount of electrodes 
was higher. It is thought that CIED complications 
are more common than acknowledged and depend 
on certain patient-related (higher in female, un-
derweight) and operator/hospital/device-related 
factors (center annual volume < 750 procedures, 
operator annual volume < 50 procedures, CRT-D 
over dual-chamber ICD, dual-chamber ICD over 
single-chamber ICD, upgrade or lead revision 
over new implantation or emergency, out-of-hours 
procedure). A new report based on meta-analysis 
of ICD complications in RCT and recent data from 
the largest international ICD registry, the United 
States National Cardiovascular Data Registry, 
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reported the overall ICD complication rate 9.1% 
over 16 months. Complications were divided to 
access-related, lead-related, generator-related and 
infection. Most frequent lead displacement, simi-
lar to our findings, was present in 3.1%, whereas 
access-related events were pneumothorax in 1.1% 
and hematoma in 1.4%. Interestingly, in-hospital 
complication rate from the RCT was 3-fold higher 
compared to ICD registry data (9.1% vs. 3.08%). 
Authors concluded that this fact may be associ-
ated with under-reporting of complications in 
registries [14]. Reporting of ICD complications in 
RCT and registries is variable and there is a need 
to standardize classification and time-window of 
evaluation of complications worldwide under the 
auspices of Heart Rhythm and Cardiac Societies 
allowing meaningful data collection, distribution, 
comparison, and practice-benchmarking.
Similar to our findings, the most often ob-
served early complication is pocket hematoma. Its 
occurrence is reported in 2.9–9.5% of cases and it 
was usually treated conservatively. Evacuation of 
hematoma is required in 0.3–2% of implantation 
and related with a 15-fold increase in infection 
risk [13, 14]. Many hematomas can be avoided by 
substantial preparing the patient before surgery. 
It should contain especially careful evaluation of 
potential thrombotic- and bleeding-risk in patients 
with indication to antiplatelet and/or antithrombotic 
therapy. In comparison to untreated patients, ASA 
therapy is associated with 2-fold higher risk of 
bleeding, and the DAPT with a 4-fold increased 
risk of bleeding [15]. In most cases, antiplatelet 
therapy can be safely discontinued for a period 
of 5–7 days, especially when recommended for 
primary prevention [16, 17]. Additionally, the use 
of heparin (UFH or LMWH) as bridging therapy 
during interruption of OAC increased the risk of 
bleeding and some authors suggest performing 
implantation procedures without OAC therapy 
cessation [18, 19]. There are no data available 
regarding periprocedural treatment of patients 
treated previously with new OAC. Given the rapid 
onset and cessation of their activities, there is no 
need to use bridging therapy with LMWH, and 
after surgery this treatment should be resumed 
soon after reaching an effective hemostasis [20].
Limitations of the study
There are several limitations of our analysis. 
The retrospective nature of our analysis is a po-
tential weakness. Even after data adjustment, the 
results could be biased by potentially important 
parameters that are not available in the registry, 
despite using the multivariable analysis. Another 
limitation is the duration of follow-up. Ideally, all 
patients would be followed until death or replace-
ment of the ICD/CRT-D.
Conclusions
Despite significant technological progress in 
ICD/CRT-D therapy, complication occurrence is 
still substantial. Most complications are recorded 
in the early post-implantation phase. Analysis 
of complication type and frequency seems to be 
essential in helping avoid adverse events in the 
future and strongly supports the need of routinely 
performed follow-up.
To conclude: in modern practice, the incidence 
of complications related with ICD/CRT-D implan-
tations remains considerable. Substantial part of 
complications occurs in early time-window after 
surgery. Thorough analysis of complication type 
and frequency seems to be essential in helping 
adjust local policies to lower the numbers of future 
adverse events and strongly supports the need of 
routinely performed follow-up.
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